PDE7B Is Involved in Nandrolone Decanoate Hydrolysis in Liver Cytosol and Its Transcription Is Up-Regulated by Androgens in Hepg2
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Potential of Guggulsterone, a Farnesoid X Receptor Antagonist, In
Exploration of Targeted Anti-tumor Therapy Open Access Review Potential of guggulsterone, a farnesoid X receptor antagonist, in the prevention and treatment of cancer Sosmitha Girisa , Dey Parama , Choudhary Harsha , Kishore Banik , Ajaikumar B. Kunnumakkara* Cancer Biology Laboratory and DBT-AIST International Center for Translational and Environmental Research (DAICENTER), Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, Assam 781039, India *Correspondence: Ajaikumar B. Kunnumakkara, Cancer Biology Laboratory and DBT-AIST International Center for Translational and Environmental Research (DAICENTER), Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, Assam 781039, India. [email protected]; [email protected] Academic Editor: Gautam Sethi, National University of Singapore, Singapore Received: August 8, 2020 Accepted: September 14, 2020 Published: October 30, 2020 Cite this article: Girisa S, Parama D, Harsha C, Banik K, Kunnumakkara AB. Potential of guggulsterone, a farnesoid X receptor antagonist, in the prevention and treatment of cancer. Explor Target Antitumor Ther. 2020;1:313-42. https://doi.org/10.37349/ etat.2020.00019 Abstract Cancer is one of the most dreadful diseases in the world with a mortality of 9.6 million annually. Despite the advances in diagnosis and treatment during the last couple of decades, it still remains a serious concern due to the limitations associated with currently available cancer management strategies. Therefore, alternative strategies are highly required to overcome these glitches. The importance of medicinal plants as primary healthcare has been well-known from time immemorial against various human diseases, including cancer. Commiphora wightii that belongs to Burseraceae family is one such plant which has been used to cure various ailments in traditional systems of medicine. -
(12) United States Patent (10) Patent No.: US 6,503,894 B1 Dudley Et Al
USOO6503894B1 (12) United States Patent (10) Patent No.: US 6,503,894 B1 Dudley et al. (45) Date of Patent: Jan. 7, 2003 (54) PHARMACEUTICAL COMPOSITION AND 5,460.820 A 10/1995 Ebert et al. METHOD FOR TREATING 5,610,150 A 3/1997 Labrie HYPOGONADISM 5,629,021. A 5/1997 Wright 5,641,504. A 6/1997 Lee et al. (75) Inventors: Robert E. Dudley, Kenilworth, IL 5,643,899 A 7/1997 Elias et al. (US); S. George Kottayil, Long Grove, (List continued on next page.) IL (US); Olivier Palatchi, L'Hayles FOREIGN PATENT DOCUMENTS Roses (FR) DE 3238984 10/1982 (73) Assignees: Unimed Pharmaceuticals, Inc., EP O581.587 A2 2/1994 Marietta, GA (US); Laboratories EP O197753 10/1996 Besins Iscovesco, Herndon, VA (US) EP O804926 4/1997 FR 2515041 4/1983 (*) Notice: Subject to any disclaimer, the term of this FR 2518879 7/1983 patent is extended or adjusted under 35 FR 2519252 7/1983 U.S.C. 154(b) by 0 days. FR 2.705572 12/1994 GB 2109231 6/1983 (21) Appl. No.: 09/651,777 WO WO 93/25168 A1 12/1993 WO 9408590 4/1994 (22) Filed: Aug. 30, 2000 WO 9421230 9/1994 WO 9421271 9/1994 (51) Int. Cl................................................. A61K 31/56 WO WO-96/27372 A1 * 9/1996 .......... A61 K/31/21 (52) U.S. Cl. ........................................ 514/178; 514/177 WO 9636339 11/1996 (58) Field of Search ................................. 514/178, 396, WO 9743989 11/1997 514/406, 415, 177 WO 98O8547 3/1998 WO 9824451 6/1998 (56) References Cited WO WO 98/34621 A1 8/1998 U.S. -
Nandrolone Decanoate Enhances Hypothalamic Biogenic Amines in Rats
Nandrolone Decanoate Enhances Hypothalamic Biogenic Amines in Rats 1 1 2 2 TETSURO TAMAKI , TAKEMASA SHIRAISHI , HIROSHI TAKEDA , TERUHIKO MATSUMIYA , 3 3,4 ROLAND R. ROY , and V. REGGIE EDGERTON 1Department of Physiology, Division of Human Structure and Function, and 2Department of Pharmacology, Tokyo Medical College, Tokyo, JAPAN; and 3Brain Research Institute and 4Department of Physiological Science, University of California, Los Angeles, CA ABSTRACT TAMAKI, T., T. SHIRAISHI, H. TAKEDA, T. MATSUMIYA, R. R. ROY, and V. R. EDGERTON. Nandrolone Decanoate Enhances Hypothalamic Biogenic Amines in Rats. Med. Sci. Sports Exerc., Vol. 35, No. 1, pp. 32–38, 2003. Purpose: To identify possible mechanisms for an anabolic-androgenic steroid induced increase in aggressive behavior and work capacity, the levels of some biogenic amines considered to be closely related to a systemic hyper-adrenergic state were measured in selected regions of the brain. Methods: Wistar male rats were divided randomly into five groups: nontreated (control), oil-vehicle-treated (vehicle) or one of three (therapeutic dose and 10- or 100-fold higher dose) anabolic-androgenic steroid-treated (steroid-1, -2, -3) groups. Rats in the steroid and vehicle groups were given a single dose of nandrolone decanoate or oil vehicle, respectively, one week before tissue sampling. The levels of norepinephrine (NE) and its metabolite, 4-hydroxy-3-methoxyphenylglycol (MHPG), serotonin (5-HT) and its metabolite, 5-hydroxy- indole-3-acetic acid (5-HIAA) were measured in the cerebral cortex, hypothalamus and cerebellum by high-performance liquid chromatography. Immunostaining for c-fos was performed as a confirmation of increased neural activity. Results: The levels of NE and MHPG were increased by ~2- and ~7-fold in the hypothalamus of the steroid-2 compared with the control and vehicle groups. -
New Long-Acting Androgens
World J Urol (2003) 21: 306–310 DOI 10.1007/s00345-003-0364-x TOPIC PAPER Louis J. Gooren New long-acting androgens Received: 16 September 2003 / Accepted: 17 September 2003 / Published online: 9 October 2003 Ó Springer-Verlag 2003 Abstract Testosterone substitution treatment aims to are usually irreversible. The consequence is that life-long replace physiological actions of endogenous testosterone androgen replacement is required. Patient compliance by steadily maintaining physiological blood levels of with life-long androgen replacement depends on conve- testosterone. The underlying conditions rendering nient pharmaceutical formulations ensuring continuity androgen replacement necessary are usually irreversible. of androgen replacement. The benefits of androgen The consequence is that almost life-long androgen replacement therapy are clear, but the delivery of tes- replacement is required. Patient compliance with life- tosterone to hypogonadal men in a way that approxi- long androgen replacement depends on convenient mates normal levels and patterns still poses a therapeutic pharmaceutical formulations ensuring continuity of challenge. Among experts, there is consensus that the androgen replacement. Therefore, they must be conve- major goal of testosterone substitution is ‘‘to replace nient in usage with a relative independence of medical testosterone levels at as close to physiological concen- services. In elderly man, safety of androgen replacement trations as is possible’’ [18]. General agreements about therapy is a concern but in younger subjects (below the such an androgen replacement therapy are (1) a delivery age of 50 years) side effects of androgens are usually of the physiological amount of testosterone (3-10 mg/d); minimal. For them, long-acting testosterone prepara- (2) consistent levels of testosterone, 5a-dihydrotestos- tions are well suited. -
The Format of This Leaflet Was Determined by the Ministry of Health and Its Content Was Checked and Approved by It on July 2012
The format of this leaflet was determined by the Ministry of Health and its content was checked and approved by it on July 2012 1. NAME OF THE MEDICINAL PRODUCT PROGYLUTON Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Calendar-pack containing 11 white tablets of 2 mg estradiol valerate each, plus 10 light brown tablets of 2 mg estradiol valerate and 0.5 mg norgestrel each. 3. PHARMACEUTICAL FORM Coated tablets. 4. CLINICAL PARTICULARS 4.1 Therapeutic indication Two phase preparation for climacteric and cycle disturbances. 4.2 Posology and method of administration Proguluton is a cyclic HRT product. One tablet is to be taken orally once a day for 21 days, followed by a 7 day tablet free interval. Therefore each new pack is started after a 28 day cycle. The white tablets should be taken from days 1 to 11 followed by the brown tablets from days 12 to 21. It is recommended that the tablets are taken at the same time every day For initiation and continuation of treatment of peri- and post-menopausal symptoms the lowest effective dose for the shortest duration (see also Section 4.4) should be used. For women still having periods, the first tablet should be taken on the 5th day of their menstrual period. If menstruation has stopped, or is infrequent or sporadic, then the first tablet can be taken any time If the patient is being transferred from a continuous HRT product, the patient may start Progyluton on any convenient day. For those transferring from a cyclic or sequential product, Progylton should be started following completion of the previous regimen If a tablet is missed, it should be taken as soon as possible, unless it is more than 12 hours late. -
Download News 2/2020
Polymere und Fluoreszenz Gleichgewicht der 360°-Trinkwasseranalyse Kräfte Trilogie Fluoreszenzspektroskopie von Basispolymeren aus der Leistung und Robustheit in Automatische, simultane Industrie Einklang mit Empfindlichkeit und schnelle Analyse von und Geschwindigkeit Pestiziden INHALT APPLIKATION »Plug und Play«-Lösung für das Krankheits-Screening – MALDI-8020 zum Screening der Sichelzellen anämie 4 Maßgeschneiderte Software- Lösungen für jede Messung – Makro-Programmierung für Shimadzu UV-Vis und FTIR 8 Auf der sicheren Seite: Steroid - nachweis in Arzneimitteln und Nahrungsergänzungsmitteln mit einem LCMS-8045 11 MSn-Analyse nicht-derivatisier- ter und Mtpp-derivatisierter Peptide – Zwei aktuelle Unter- suchungen zur Anwendung von LC-MS-IT-TOF-Geräten 18 Polymere und Fluoreszenz – Teil 2: Wieviel Fluoreszenz zeigt ein Poly mer für eine Qualitäts - kontrolle? 26 PRODUKTE Gleichgewicht der Kräfte – LCMS-8060NX: Leistung und Robustheit mit Empfindlichkeit, und Geschwindigkeit 7 360°-Trinkwasseranalyse: Episode 2 – Automatische, simul- Enrico Davoli mit dem PESI-MS-System – einem Gerät zu reinen Forschungszwecken (research-use only = RUO) tane und schnelle Analyse von Pestiziden mit Online-SPE und UHPLC-MS/MS 14 Vielseitiges Tool für die Automobil - industrie – Neue HMV-G3 Serie 17 Eine globale Lösung Kopfschmerz ade – Anleitung zur Auswahl der idealen C18-Säule 22 Validierte Methode für monoklo- nale Antikörper-Medikamente – dank globaler Bewertung der nSMOL-Methodik in menschlichem Serum 24 AKTUELLES Zusammenarbeit Eine globale Lösung -
Identification of Steroid Esters in Cattle Hair at Ultra-Trace Levels
Application Note Identification of Steroid Esters in Cattle Hair at Ultra-Trace Levels Emmanuelle Bichon, Lauriane Rambaud, Stephanie Christien, Aurélien Béasse, Stephanie Prevost, Fabrice Monteau, Bruno Le Bizec, Peter Hancock Waters Corporation Abstract The aim of this study is to address some of the analytical challenges previously described when analyzing a wide range of steroid esters (boldenone, nandrolone, estradiol, and testosterone) in cattle hair. Benefits ■ Unambiguous determination of steroid esters at ng/g level in cattle hair ■ Method is five times faster than the established GC-MS/MS method, with all esters included in a single run ■ Provides an efficient and additional confirmatory method to overcome any inconclusive urine analyses ■ Allows the potential to improve the detection of all banned substances in cattle hair by reducing matrix interference ■ Provides the ability to detect and identify compounds for a long time after administration Introduction The safety of our food supply can no longer be taken for granted. As the world changes and populations continue to grow, so will the responsibility of organizations to meet the demand of safe food supplies. One route of human exposure to veterinary substances is through the food chain as a result of malpractice or illegal activities. The steroid esters are one group of substances causing concern, which might still be used as growth promoting agents, but are now forbidden from use in breeding animals in the European Union.1 No residues of these anabolic substances should -
Schwarz, Tamar Imogen (2016) the Origin of Vertebrate Steroids in Molluscs: Uptake, Metabolism and Depuration Studies in the Common Mussel
Schwarz, Tamar Imogen (2016) The origin of vertebrate steroids in molluscs: uptake, metabolism and depuration studies in the common mussel. PhD thesis. https://theses.gla.ac.uk/7436/ Copyright and moral rights for this work are retained by the author A copy can be downloaded for personal non-commercial research or study, without prior permission or charge This work cannot be reproduced or quoted extensively from without first obtaining permission in writing from the author The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the author When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given Enlighten: Theses https://theses.gla.ac.uk/ [email protected] THE ORIGIN OF VERTEBRATE STEROIDS IN MOLLUSCS: UPTAKE, METABOLISM AND DEPURATION STUDIES IN THE COMMON MUSSEL TAMAR IMOGEN SCHWARZ Submitted in fulfilment of the requirements for the degree of Doctor of Philosophy in Molecular and Cellular Biology Institute of Molecular, Cell and Systems Biology College of Medical, Veterinary and Life Sciences University of Glasgow In collaboration with the Centre for the Environment, Fisheries and Aquaculture Science (Cefas) April 2016 ©Tamar I. Schwarz, 2016 1 Abstract Many studies have found vertebrate sex steroids, such as testosterone (T), 17 β-oestradiol (E 2) and progesterone (P) to be present in molluscan tissues. The underlying assumption of most, if not all, these studies has been that these steroids are formed endogenously and furthermore, act as reproductive hormones in the same way that they do in vertebrates (i.e. -
Transformations of Steroid Esters by Fusarium Culmorum Alina S´ Wizdor*, Teresa Kołek, and Anna Szpineter
Transformations of Steroid Esters by Fusarium culmorum Alina S´ wizdor*, Teresa Kołek, and Anna Szpineter Department of Chemistry, Agricultural University, Norwida 25, 50-375 Wrocław, Poland. Fax: 0048-071-3283576. E-mail: [email protected] * Author for correspondence and reprint requests Z. Naturforsch. 61c, 809Ð814 (2006); received April 6/May 15, 2006 The course of transformations of the pharmacological steroids: testosterone propionate, 4-chlorotestosterone acetate, 17-estradiol diacetate and their parent alcohols in Fusarium culmorum AM282 culture was compared. The results show that this microorganism is capable of regioselective hydrolysis of ester bonds. Only 4-ene-3-oxo steroid esters were hydrolyzed at C-17. 17-Estradiol diacetate underwent regioselective hydrolysis at C-3 and as a result, estrone Ð the main metabolite of estradiol Ð was absent in the reaction mixture. The alcohols resulting from the hydrolysis underwent oxidation at C-17 and hydroxylation. The same products (6- and 15α-hydroxy derivatives) as from testosterone were formed by transformation of testosterone propionate, but the quantitative composition of the mixtures obtained after transformations of both substrates showed differences. The 15α-hydroxy deriv- atives were obtained from the ester in considerably higher yield than from the parent alcohol. The presence of the chlorine atom at C-4 markedly reduced 17-saponification in 4-chloro- testosterone acetate. Only 3,15α-dihydroxy-4α-chloro-5α-androstan-17-one (the main prod- uct of transformation of 4-chlorotestosterone) was identified in the reaction mixture. 6- Hydroxy-4-chloroandrostenedione, which was formed from 4-chlorotestosterone, was not de- tected in the extract obtained after conversion of its ester. -
United States Patent (19) 11) Patent Number: 4,507,290 Archer Et Al
United States Patent (19) 11) Patent Number: 4,507,290 Archer et al. 45) Date of Patent: Mar. 26, 1985 54 ESTERS OF 17 a-ETHYNYL 52 U.S. Cl. ................................. 514/172; 260/397.4; 19-NOR-TESTOSTERONE AND 17 260/.397.5; 514/179 C-ETHYNYL-18 HOMO-19-NOR-TESTOST 58 Field of Search ...................... 260/.397.4; 424/243 ERONE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME 56) References Cited U.S. PATENT DOCUMENTS 75 Inventors: Sydney Archer, Troy, N.Y.; Giuseppe 3,959,322 5/1976 Hughes et al. ... 260/.397.4 Benagiano, Rome, Italy; Pierre 4,027,019 5/1977 Shroff............. ... 260/397.4 Crabbe, Paris, France; Egon 4,089,952 5/1978 Itil et al. .............................. 424/243 Diczfalusy, Stockholm, Sweden; Carl 4, 119,626 10/1978 Schulze et al. ... 260/397.4 Djerassi, Stanford, Calif.; Josef 4,181,721 1/1980 Speck et al. ......................... 424/243 Fried, Chicago, Ill. Primary Examiner-Elbert L. Roberts 73) Assignee: World Health Organization, Geneva, Attorney, Agent, or Firm-Cushman, Darby & Cushman Switzerland 57 ABSTRACT 21 Appl. No.: 251,914 Esters of 17 a-ethynyl 19-nor-testosterone and 17 a ethynyl-18-homo-19-nor-testosterone and the 3-oximes 22 Filed: Apr. 7, 1981 thereof having long-active contraceptive activity. 51) Int. Cl. .............................................. A61K 31/56 21 Claims, No Drawings 4,507,290 1 2 wherein R2 is acyl derived from an alicyclic carbox ESTERS OF 17 o-ETHYNYL ylic acid wherein the alicyclic moiety can have 19-NOR-TESTOSTERONE AND 17 3-6, preferably 3 and 4, carbon atoms in the ring; o-ETHYNYL-18-HOMO-19-NOR-TESTOSTERONE (d) the corresponding oxime of the ester defined in AND PHARMACEUTICAL COMPOSITIONS 5 (c); CONTAINING THE SAME (e) an ester of levo-norgestrel having the formula (II) above, wherein R2 is acyl derived from an aliphatic BACKGROUND AND SUMMARY OF THE carboxylic acid containing 5 carbon atoms, in ex INVENTION tenso pentanoic acid isomers, i.e. -
Perspectives of Contraceptive Choices for Men
Indian Jouma1 of Experimental Biology Vol. 43, November 2005, pp. 1042-1047 Review Article Perspectives of contraceptive choices for men N K Lohiya*, B Manivannan, S S Bhande, S Panneerdoss & Shipra Garg Reproductive Pbysiology Section, Department of Zoology, University of Rajasthan, Jaipur 302 004, India Apart from condoms and vasectomy, which have several limitations of their own, no other methods of contraception are available to men. Various chemical, honnonal, vas based and herbal contraceptives have been examined and few of them have reached the stage of clinica1 testing. Promising leads have been obtained from testosterone bucic1atelundecanoate, alone or in combination with levonorgestrel butanoate or cyproterone acetate, RlSUG, an injectable intra vasal contraceptive and a few herba1 products, particularly the seed products of Carica papaya. It is feasible that an ideal male contraceptive. that meets out all the essential criteria will be made available to the community in the near future. Keywords: Carica papaya, Herbal methods, Honnonal methods. Male contraception, RISUG. Vas based methods In the new millennium, India has crossed the one lead from sperm production in the testis to sperm egg billion mark. sharing 16% of the world population on interactions and fertilization in the female genital tract 2.4% of the global land area. More than 18 million need to be considered. Accordingly, the biomedical people are added every year, which is almost the options available in control of male fertility are entire population of Australia With the current trend, limited to (1) inhibition of spermatogenesis at the it is projected that India may overtake China in the level of testis, (2) inhibition of sperm maturation at year 2045 to become the most populous country in the the level of epididymis, (3) inhibition of sperm world, the distinction which no Indian would be proud transport at the level of vas deferens, (4) inhibition of of. -
Determination of Testosterone Esters in Serum by Liquid Chromatography – Tandem Mass Spectrometry (LC-MS-MS)
Department of Physics, Chemistry and Biology Final Thesis Determination of testosterone esters in serum by liquid chromatography – tandem mass spectrometry (LC-MS-MS) Erica Törnvall Final Thesis performed at National Board of Forensic Medicine 2010-06-03 LITH-IFM-EX--10/2263--SE Department of Physics, Chemistry and Biology Linköping University 581 83 Linköping, Sweden 1 Department of Physics, Chemistry and Biology Determination of testosterone esters in serum by liquid chromatography – tandem mass spectrometry (LC-MS-MS) Erica Törnvall Final Thesis performed at National Board of Forensic Medicine 2010-06-03 Supervisors Yvonne Lood Martin Josefsson Examiner Roger Sävenhed 2 Avdelning, institution Datum Division, Department Date 2010-06-03 Chemistry Department of Physics, Chemistry and Biology Linköping University Språk Rapporttyp ISBN Language Report category Svenska/Swedish Licentiatavhandling ISRN: LITH-IFM-EX--10/2263--SE Engelska/English Examensarbete _________________________________________________________________ C-uppsats D-uppsats Serietitel och serienummer ISSN ________________ Övrig rapport Title of series, numbering ______________________________ _____________ URL för elektronisk version Titel Title Determination of testosterone esters in serum by liquid chromatography – tandem mass spectrometry (LC-MS-MS) Författare Author Erica Törnvall Sammanfattning Abstract Anabolic androgenic steroids are testosterone and its derivates. Testosterone is the most important naturally existing sex hormone for men and is used for its anabolic effects providing increased muscle mass. Testosterone is taken orally or by intramuscular injection in its ester form and are available illegally in different forms of esters. Anabolic androgenic steroids are today analyzed only in urine. To differentiate between the human natural testosterone and exogenous supply the quote natural testosterone and epitestosterone is used.